BioMarin Pharmaceutical

BMRN · NASDAQ

$56.44+$1.77 (+3.24%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $54.67

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.

Employees: 3,221
Headquarters: San Rafael California, California
Listed: Jul 23, 1999
Sector: Health Care
Industry: Biotechnology
Website: biomarin.com

Leadership

BioMarin Pharmaceutical executives
Name	Title	Since	Age
Richard Meier	—	—	65
Alexander Hardy	—	2023	56
Brian Mueller	—	—	51
C. Greg Guyer	—	—	63
G. Eric Davis	—	—	54
Arpit Dave	—	—	—
Gregory Friberg	—	—	51
Cristin Hubbard	—	—	49
Rashmi Ramchandani	—	—	47
James Sabry	—	—	66
Elizabeth Anderson	—	—	67
Barbara Bodem	—	—	57
Ian Clark	—	—	65
Athena Countouriotis	—	—	53
Willard Dere	—	—	71
Mark Enyedy	—	—	61
Maykin Ho	—	—	72
Robert Hombach	—	—	59
Timothy Walbert	—	—	58

Revenue by product and region

Fiscal year ended Dec 31, 2025: $3.22B total revenue

By product

Net product revenues$3.17B98.3%
Royalty and other revenues$53.49M1.7%

Similar companies

Companies in the same industry as BioMarin Pharmaceutical

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.